Dogwood Therapeutics, Inc. (Nasdaq: DWTX) reported financial results for the first quarter ended March 31, 2026, emphasizing significant pipeline milestones and a strong operational start to the year. The company is advancing two non-opioid candidates for pain and neuropathy: Halneuron and SP16.
Halneuron, a NaV 1.7 inhibitor for chemotherapy-induced neuropathic pain (CINP), has enrolled 164 patients in its Phase 2b study, with top-line results expected in fall 2026. The drug has received Fast Track designation from the FDA. Separately, SP16, an LRP1 agonist for chemotherapy-induced peripheral neuropathy (CIPPN), received IND approval from the FDA and will begin enrollment in mid-2026. The Phase 1b trial is fully funded by the National Cancer Institute and conducted at the University of Virginia.
CEO Greg Duncan stated that the company executed a global development license for its legacy combination antiviral assets in the quarter. Financially, Dogwood completed a financing of up to $26.9 million in January 2026, with $12.5 million received in gross proceeds. Cash on hand stood at $13.2 million as of March 31, 2026, providing operational runway into the fourth quarter of 2026.
Research and development expenses for Q1 2026 were $2.7 million, up from $2.4 million in Q1 2025, driven by increased drug development costs for Halneuron and personnel costs. General and administrative expenses rose to $2.4 million from $2.0 million, primarily due to higher salaries and personnel costs. Net loss attributable to common stockholders was $5.0 million, or $0.15 per share, compared to a net loss of $12.2 million, or $8.45 per share, in the prior-year period. The prior year included a $6.1 million loss on debt conversion with a related party.
Dogwood Therapeutics focuses on developing first-in-class non-opioid medicines for pain and neuropathic disorders. Its largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., listed on the Hong Kong Stock Exchange. For more information, visit www.dwtx.com. The company also reminded that any payments from development and commercialization partnerships that qualify as upfront or milestone payments will be delivered to the rights agent for CVR holders.
